S&P 500   3,115.96 (-0.19%)
DOW   27,931.37 (-0.37%)
QQQ   202.92 (-0.07%)
CGC   15.25 (+7.24%)
BABA   185.47 (+0.47%)
GE   11.31 (-1.14%)
T   38.52 (-2.80%)
ACB   2.37 (+3.95%)
F   8.90 (-0.56%)
BAC   32.87 (-0.27%)
DIS   147.49 (-0.11%)
S&P 500   3,115.96 (-0.19%)
DOW   27,931.37 (-0.37%)
QQQ   202.92 (-0.07%)
CGC   15.25 (+7.24%)
BABA   185.47 (+0.47%)
GE   11.31 (-1.14%)
T   38.52 (-2.80%)
ACB   2.37 (+3.95%)
F   8.90 (-0.56%)
BAC   32.87 (-0.27%)
DIS   147.49 (-0.11%)
S&P 500   3,115.96 (-0.19%)
DOW   27,931.37 (-0.37%)
QQQ   202.92 (-0.07%)
CGC   15.25 (+7.24%)
BABA   185.47 (+0.47%)
GE   11.31 (-1.14%)
T   38.52 (-2.80%)
ACB   2.37 (+3.95%)
F   8.90 (-0.56%)
BAC   32.87 (-0.27%)
DIS   147.49 (-0.11%)
S&P 500   3,115.96 (-0.19%)
DOW   27,931.37 (-0.37%)
QQQ   202.92 (-0.07%)
CGC   15.25 (+7.24%)
BABA   185.47 (+0.47%)
GE   11.31 (-1.14%)
T   38.52 (-2.80%)
ACB   2.37 (+3.95%)
F   8.90 (-0.56%)
BAC   32.87 (-0.27%)
DIS   147.49 (-0.11%)
Log in

Neurotrope Stock Price, Forecast & Analysis (NASDAQ:NTRP)

$0.72
+0.01 (+1.41 %)
(As of 11/19/2019 10:04 AM ET)
Today's Range
$0.69
Now: $0.72
$0.74
50-Day Range
$0.64
MA: $0.69
$0.76
52-Week Range
$0.63
Now: $0.72
$8.40
Volume223,900 shs
Average Volume208,573 shs
Market Capitalization$9.41 million
P/E RatioN/A
Dividend YieldN/A
Beta2.07
Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTRP
CUSIPN/A
Phone973-242-0005

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$2.05 per share

Profitability

Net Income$-11,020,000.00

Miscellaneous

Employees6
Market Cap$9.41 million
Next Earnings Date11/19/2019 (Estimated)
OptionableOptionable

Receive NTRP News and Ratings via Email

Sign-up to receive the latest news and ratings for NTRP and its competitors with MarketBeat's FREE daily newsletter.


Neurotrope (NASDAQ:NTRP) Frequently Asked Questions

What is Neurotrope's stock symbol?

Neurotrope trades on the NASDAQ under the ticker symbol "NTRP."

How were Neurotrope's earnings last quarter?

Neurotrope Inc (NASDAQ:NTRP) released its quarterly earnings results on Tuesday, October, 30th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.05. View Neurotrope's Earnings History.

When is Neurotrope's next earnings date?

Neurotrope is scheduled to release their next quarterly earnings announcement on Tuesday, November 19th 2019. View Earnings Estimates for Neurotrope.

What price target have analysts set for NTRP?

2 brokers have issued 1 year price targets for Neurotrope's stock. Their forecasts range from $1.00 to $16.00. On average, they expect Neurotrope's stock price to reach $8.50 in the next twelve months. This suggests a possible upside of 1,080.6% from the stock's current price. View Analyst Price Targets for Neurotrope.

What is the consensus analysts' recommendation for Neurotrope?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurotrope in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Neurotrope.

What are Wall Street analysts saying about Neurotrope stock?

Here are some recent quotes from research analysts about Neurotrope stock:
  • 1. According to Zacks Investment Research, "Neurotrope, Inc. is focused primarily on the development and commercialization of Alzheimer's disease therapeutic products related diagnostics. The Company develops and markets two product platforms, including a non-invasive diagnostic test for Alzheimer's disease and a drug candidate called bryostatin for the treatment of Alzheimer's disease, both of which are in the clinical testing stage. Neurotrope, Inc. is based in Plantation, Florida. " (11/1/2019)
  • 2. Maxim Group analysts commented, "Neurotrope announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI) for the development of Bryostatin-1 in acute lymphoblastic leukemia (ALL)." (2/5/2019)

Has Neurotrope been receiving favorable news coverage?

Media stories about NTRP stock have trended somewhat positive on Tuesday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Neurotrope earned a coverage optimism score of 1.1 on InfoTrie's scale. They also gave news stories about the company a news buzz of 1.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the near future. View News Stories for Neurotrope.

Are investors shorting Neurotrope?

Neurotrope saw a increase in short interest in October. As of October 31st, there was short interest totalling 814,000 shares, an increase of 86.0% from the September 30th total of 437,700 shares. Based on an average trading volume of 563,500 shares, the days-to-cover ratio is presently 1.4 days. Approximately 8.4% of the company's stock are sold short. View Neurotrope's Current Options Chain.

Who are some of Neurotrope's key competitors?

What other stocks do shareholders of Neurotrope own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurotrope investors own include Sarepta Therapeutics (SRPT), Fibrocell Science (FCSC), Neos Therapeutics (NEOS), Alibaba Group (BABA), Canopy Growth (CGC), Intel (INTC), Iovance Biotherapeutics (IOVA), JD.Com (JD), Pieris Pharmaceuticals (PIRS) and Celgene (CELG).

Who are Neurotrope's key executives?

Neurotrope's management team includes the folowing people:
  • Dr. Charles S. Ryan, CEO & Director (Age 55)
  • Dr. Daniel L. Alkon, Pres & Chief Scientific Officer (Age 77)
  • Mr. Robert Weinstein, CFO, Exec. VP, Sec. & Treasurer (Age 59)
  • Dr. Michael Ciraolo, Gen. Counsel & COO (Age 46)
  • Mr. Jeffrey Benison, Director of Corp. Communications

How do I buy shares of Neurotrope?

Shares of NTRP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Neurotrope's stock price today?

One share of NTRP stock can currently be purchased for approximately $0.72.

How big of a company is Neurotrope?

Neurotrope has a market capitalization of $9.41 million. The company earns $-11,020,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. Neurotrope employs 6 workers across the globe.View Additional Information About Neurotrope.

What is Neurotrope's official website?

The official website for Neurotrope is http://www.neurotropebioscience.com/.

How can I contact Neurotrope?

Neurotrope's mailing address is 1185 AVENUE OF THE AMERICAS 3RD FLOOR, NEW YORK NY, 10036. The company can be reached via phone at 973-242-0005 or via email at [email protected]


MarketBeat Community Rating for Neurotrope (NASDAQ NTRP)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  159 (Vote Outperform)
Underperform Votes:  189 (Vote Underperform)
Total Votes:  348
MarketBeat's community ratings are surveys of what our community members think about Neurotrope and other stocks. Vote "Outperform" if you believe NTRP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTRP will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/19/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel